CURE Epilepsy’s grant programs seek to accelerate promising research leading to new treatments and cures for people living with epilepsy. CURE prioritizes innovative projects that address its mission to cure epilepsy, affirming CURE's core belief that the only acceptable final goal is “no seizures, no side-effects.”
CURE funds research that has the potential to truly transform and save lives. The purpose of this funding opportunity is to stimulate and accelerate discovery and development of new, transformative therapies for epilepsy, moving promising, well-supported preclinical and/or clinical research closer to clinical application. The award is intended to support nimble development of data necessary to attract larger commercialization funding opportunities and is not intended to replace those opportunities. Projects based on novel biological pathways and/or highly differentiated therapeutic approaches which are likely to have a high probability of success transitioning to clinical development are strongly encouraged.
Projects supported by this award mechanism should advance research to clinical trial readiness through development of biomarkers, optimization of new entities based on entities with established proof-of-concept including pharmacokinetics/pharmacodynamics, safety profiles and/or improved formulations, as well as studies that advance preclinical findings to pilot clinical trials. Proof-of-concept of the entity being developed is required.
Prospective pilot clinical trials where limited testing of a novel intervention is needed to inform the next step in the translational research may be considered. Priority areas include:
Budgets may include salary support for the Principal Investigator (PI), technical staff and/or co-PIs, supplies, animal costs, vendor costs, limited equipment costs, and travel to an epilepsy-related conference only if the PI is presenting his/her CURE Epilepsy-funded research.
